EyePoint to Report Third Quarter 2025 Financial Results on November 5, 2025

Rhea-AI Summary

EyePoint (NASDAQ: EYPT) will report its third quarter 2025 financial results on November 5, 2025 and will host a conference call and live webcast at 8:30 a.m. ET.

Investors can register for the live audio conference via the provided audio conference link and access a live audio webcast and replay through the company's Investors section at www.eyepointpharma.com.

WATERTOWN, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 5, 2025 to report its third quarter 2025 financial results and highlight recent corporate developments.

To access the live conference call, please register using the audio conference link: https://edge.media-server.com/mmc/p/fgkir3sg. A live audio webcast of the event can be accessed via the Investors section of the Company website at www.eyepointpharma.com. A webcast replay will also be available on the corporate website at the conclusion of the call.

About EyePoint

EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU^™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E^™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.

The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.

EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.

Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.

DURAVYU^™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901 (vorolanib intravitreal insert). DURAVYU is an investigational medicinal product and is not authorized for sale in any country at the present time. FDA approval in the United States and marketing authorization in any other country and the timeline for potential approval or authorization is uncertain.

Investors:

Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:

Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com

FAQ

When will EyePoint (EYPT) report third quarter 2025 results?

EyePoint will report Q3 2025 results on November 5, 2025 with a call at 8:30 a.m. ET.

How can investors access the EyePoint (EYPT) November 5, 2025 earnings call?

Investors can register via the provided audio conference link and listen to a live audio webcast on the company's Investors webpage.

Will a replay of the EyePoint (EYPT) November 5, 2025 call be available?

Yes, a webcast replay will be available on EyePoint's corporate website after the conclusion of the call.

What time is the EyePoint (EYPT) Q3 2025 conference call?

The conference call and live webcast begin at 8:30 a.m. ET on November 5, 2025.

Where is the official webcast for EyePoint (EYPT) earnings hosted?

The live audio webcast and replay are hosted in the Investors section of www.eyepointpharma.com.